uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU) Wisdom Lake Academy of Pharmacy to develop innovative chimeric antigen receptor natural killer (CAR-NK) cell therapies. The collaboration aims to advance the field of immunotherapy by creating two distinct types of CAR-NK cell treatments.
The first therapy, acRNA-CAR-NK, will integrate uBriGene’s proprietary self-cyclizing RNA (acRNA) and mRNA technologies with a novel lipid nanoparticle (LNP) system. This approach is designed to enhance the stability and effectiveness of the CAR-NK cells. The second therapy, TIMP-CAR-NK, will combine metalloproteinase inhibitors (TIMPs) with CAR-NK cells. The addition of TIMPs is intended to boost the ability of NK cells to infiltrate solid tumors, thereby increasing their anti-tumor activity.
This partnership brings together uBriGene’s expertise in genetic engineering and XJTLU’s academic resources, marking a significant step forward in the development of next-generation cellular immunotherapies. The joint efforts aim to improve the clinical outcomes for patients with solid tumors by enhancing the natural killer cells’ capabilities to target and destroy cancer cells.- Flcube.com
